Teriparatide: Uses, Mechanism, and Side Effects

Key takeaways

• Teriparatide is a parathyroid hormone analog used to build bone density in people at high risk of fracture.
• It is approved for postmenopausal women, certain men, and patients on long-term glucocorticoid therapy.
• Teriparatide carries no boxed warning on its current label.
• More than 197 clinical trials have studied this compound, spanning bone metabolism and treatment sequencing.
• The most reported side effects involve musculoskeletal pain, dizziness, and falls, based on adverse event reports rather than confirmed causation.

What Teriparatide Is

Teriparatide is a parathyroid hormone analog classified as a Parathyroid Hormone Analog. It mimics the active portion of endogenous parathyroid hormone, the body's main regulator of calcium and phosphate balance. By binding the same high-affinity receptors as natural parathyroid hormone, it influences bone remodeling, kidney handling of calcium and phosphate, and calcium absorption in the intestine. This receptor activity is what allows the drug to promote new bone formation over time.

What Teriparatide Is Approved For

Teriparatide is approved to treat postmenopausal women with osteoporosis who face a high risk of fracture, including those who have already had an osteoporotic fracture or who have not responded to other therapies. In this population, it lowers the risk of both vertebral and nonvertebral fractures. It is also approved to increase bone mass in men with primary or hypogonadal osteoporosis who are at high fracture risk or have not tolerated other treatments. A third approved use covers men and women with osteoporosis caused by sustained systemic glucocorticoid therapy at daily doses equivalent to 5 mg or more of prednisone. The current label does not carry a boxed warning.

What The Evidence Shows

Teriparatide has been studied across 197 registered clinical trials. One completed Phase 2 trial examined adding phosphorus to standard osteoporosis drug treatment. A separate Phase 2 study looked at how the length of teriparatide administration affects bone metabolism and bone mineral density before patients transition to denosumab therapy. A newer trial, still recruiting, is investigating sequential therapies used after osteoanabolic treatment like teriparatide.

Reported Side Effects

Adverse event reports for teriparatide are dominated by musculoskeletal and neurological complaints rather than a single dominant reaction. Arthralgia (8,673 reports), pain in extremity (8,349), back pain (5,919), and general pain (7,534) account for a large share of submissions, alongside nausea (8,982). Dizziness (8,287) and falls (7,893) also appear frequently, along with fatigue (7,181). These figures reflect the number of reports submitted to a safety database, not confirmed rates of occurrence or proof that the drug caused each event.